Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplemental Figure S3: Repeated mXTX301 dosing was well tolerated and resulted in dose dependent TGI in mice bearing large (~360mm3) MC38 tumors (a) C57BL/6J mice were implanted subcutaneously with MC38 tumor cells and received a single intravenous injection of mXTX301, unmasked control, or vehicle (PBS) at indicated dose levels (N=12 per group). Tumor measurements were taken two/three times a week. Animals were euthanized due to health issues or body weight loss. The data represent individual survival curves. CR: complete regression, EU: euthanized. (b) C57BL/6J mice were implanted subcutaneously with MC38 tumor cells and received a total of 3 doses marked by red arrows of mXTX301. Body weight was monitored over time (c) Survival prolongation was assessed by Gehan-Breslow-Wilcoxon test comparison at all study time points (until Day 27). ***p = 0.0001; ****p < 0.0001.